Solid Biosciences Inc. (SLDB): who owns it and who trades it
As of Nov 16, 2026, SLDB insiders reported 27 open-market sales worth $2.7M and no purchases in the last 12 months, with 1% of the sale value made under pre-set 10b5-1 plans. The largest seller was Alexander Cumbo (CEO), with $984K. 4 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Solid Biosciences
From the latest filingsOverall: more selling than buying. Insiders mostly sold. Funds mostly bought. Famous investors was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SLDB
156 funds and institutions reported SLDB shares worth $1.1B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is Ra Capital Management, L.P. with 12.2%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 12.04M | 12.23% | $120M | +29% |
| Perceptive Advisors LLC | 11.91M | 12.10% | $119M | No change |
| Bain Capital Life Sciences Investors, LLC | 9.81M | 9.97% | $98M | No change |
| Siren, L.L.C. | 7.69M | 7.82% | $76.8M | No change |
| BlackRock, Inc. | 6.93M | 7.05% | $69.3M | +40% |
| FMR LLC (Fidelity) | 6.88M | 6.99% | $68.7M | +91% |
| Armistice Capital, LLC | 4.28M | 4.35% | $42.7M | +34% |
| State Street Corp | 4.18M | 4.24% | $41.7M | +271% |
| Jupiter Topco LLC | 4.04M | 4.11% | $40.4M | – |
| Vanguard Capital Management LLC | 4.01M | 4.08% | $40.1M | +50% |
| Rtw Investments, LP | 3.89M | 3.96% | $38.9M | – |
| Deep Track Capital, LP | 3.57M | 3.62% | $35.6M | No change |
| Franklin Resources Inc | 3.44M | 3.50% | $34.4M | +57% |
| Citadel Advisors LLC | 2.82M | 2.86% | $28.1M | +8% |
| Alyeska Investment Group, L.P. | 2.28M | 2.32% | $22.8M | No change |
| Ameriprise Financial Inc | 2.23M | 2.26% | $22.2M | -9% |
| Vestal Point Capital, LP | 2.16M | 2.20% | $21.6M | -57% |
| Redmile Group, LLC | 1.95M | 1.98% | $19.5M | -3% |
| Geode Capital Management, LLC | 1.94M | 1.97% | $19.4M | +50% |
| Goldman Sachs Group Inc | 1.60M | 1.63% | $16M | +71% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SLDB insiders reported $0 of open-market purchases and $2.7M of sales. 1% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Oct 19, 2026 | Gabriel Brooks | Chief Medical Officer | Sale plan | 4,374 | $5.62 | $24.6K | Form 4 |
| Feb 18, 2026 | Alexander Cumbo | CEO | Sale | 16,644 | $5.82 | $96.9K | Form 4 |
| Feb 18, 2026 | Jessie Hanrahan | Chief Regulatory Officer | Sale | 4,134 | $5.82 | $24.1K | Form 4 |
| Feb 18, 2026 | Ilan Ganot | Director | Sale | 2,658 | $5.82 | $15.5K | Form 4 |
| Feb 18, 2026 | Paul Herzich | Chief Technology Officer | Sale | 3,616 | $5.82 | $21K | Form 4 |
| Feb 18, 2026 | David T Howton | Chief Operating Officer | Sale | 7,469 | $5.82 | $43.5K | Form 4 |
| Feb 18, 2026 | Kevin Tan | CFO | Sale | 5,404 | $5.82 | $31.5K | Form 4 |
| Feb 4, 2026 | David T Howton | Chief Operating Officer | Sale | 18,894 | $6.44 | $122K | Form 4 |
| Feb 4, 2026 | Alexander Cumbo | CEO | Sale | 48,913 | $6.44 | $315K | Form 4 |
| Feb 4, 2026 | Ilan Ganot | Director | Sale | 7,205 | $6.44 | $46.4K | Form 4 |
| Feb 4, 2026 | Kevin Tan | CFO | Sale | 14,783 | $6.44 | $95.2K | Form 4 |
| Feb 4, 2026 | Gabriel Brooks | Chief Medical Officer | Sale | 12,616 | $6.44 | $81.2K | Form 4 |
| Feb 4, 2026 | Jessie Hanrahan | Chief Regulatory Officer | Sale | 12,348 | $6.44 | $79.5K | Form 4 |
| Feb 4, 2026 | Paul Herzich | Chief Technology Officer | Sale | 10,905 | $6.44 | $70.2K | Form 4 |
| Feb 2, 2026 | Kevin Tan | CFO | Sale | 26,837 | $6.44 | $173K | Form 4 |
| Feb 2, 2026 | Alexander Cumbo | CEO | Sale | 80,258 | $6.44 | $517K | Form 4 |
| Feb 2, 2026 | Jessie Hanrahan | Chief Regulatory Officer | Sale | 26,535 | $6.44 | $171K | Form 4 |
| Feb 2, 2026 | Gabriel Brooks | Chief Medical Officer | Sale | 28,335 | $6.44 | $182K | Form 4 |
| Feb 2, 2026 | David T Howton | Chief Operating Officer | Sale | 37,771 | $6.44 | $243K | Form 4 |
| Feb 2, 2026 | Paul Herzich | Chief Technology Officer | Sale | 26,250 | $6.44 | $169K | Form 4 |
| Jan 28, 2026 | Ilan Ganot | Director | Sale | 191 | $6.59 | $1.3K | Form 4 |
| Jan 13, 2026 | Kevin Tan | CFO | Sale | 5,704 | $5.27 | $30.1K | Form 4 |
| Jan 5, 2026 | Ilan Ganot | Director | Sale | 1,053 | $5.43 | $5.7K | Form 4 |
| Dec 3, 2025 | David T Howton | Chief Operating Officer | Sale | 4,932 | $5.11 | $25.2K | Form 4 |
| Dec 3, 2025 | Alexander Cumbo | CEO | Sale | 10,808 | $5.11 | $55.2K | Form 4 |
| Dec 3, 2025 | Jessie Hanrahan | Chief Regulatory Officer | Sale | 4,483 | $5.11 | $22.9K | Form 4 |
| Dec 3, 2025 | Paul Herzich | Chief Technology Officer | Sale | 2,701 | $5.11 | $13.8K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Alexander Cumbo | President and CEO, Director | – | $984K | Feb 18, 2026 |
| David T Howton | Chief Operating Officer | – | $434K | Feb 18, 2026 |
| Kevin Tan | CFO & Treasurer | – | $330K | Feb 18, 2026 |
| Jessie Hanrahan | Chief Regulatory Officer | – | $297K | Feb 18, 2026 |
| Gabriel Brooks | Chief Medical Officer | – | $288K | Oct 19, 2026 |
| Paul Herzich | Chief Technology Officer | – | $274K | Feb 18, 2026 |
| Ilan Ganot | Director | – | $68.8K | Feb 18, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SLDB short interest
High short interest. 11.9% of SLDB shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 46%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 13.30M SLDB shares were sold short, 11.9% of the shares outstanding, up 8.2% from the report before. At the average daily volume of 1.24M shares, buying them all back would take about 10.7 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 13.30M | 11.92% | +8% | 1.24M | 10.7 |
| Oct 15, 2026 | 12.30M | 11.47% | -3% | 1.44M | 8.5 |
| Sep 30, 2026 | 12.73M | 11.87% | -26% | 1.66M | 7.7 |
| Sep 15, 2026 | 17.11M | 15.95% | +4% | 871,453 | 19.6 |
| Aug 31, 2026 | 16.38M | 15.28% | -1% | 866,303 | 18.9 |
| Aug 14, 2026 | 16.62M | 15.50% | -2% | 847,638 | 19.6 |
| Jul 31, 2026 | 17.04M | 17.31% | -4% | 1.05M | 16.2 |
| Jul 15, 2026 | 17.67M | 17.96% | -3% | 1.58M | 11.2 |
| Jun 30, 2026 | 18.27M | 18.57% | +57% | 4.00M | 4.6 |
| Jun 15, 2026 | 11.61M | 11.80% | +21% | 1.31M | 8.8 |
| May 29, 2026 | 9.60M | 9.76% | +5% | 1.02M | 9.4 |
| May 15, 2026 | 9.10M | 9.25% | +3% | 1.33M | 6.8 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Solid Biosciences company events
Solid Biosciences filed 5 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Aug 6, 2026.
- Aug 6, 2026AnnouncementSolid Biosciences Inc. filed a prospectus supplement under the Company’s universal shelf registration statement on Form S-3 (File No. 333-287325) that was originally filed with the Securities and Exchange Commission on May 15, 2025 and was declared effective by the SEC on May 27, 2025, relating to… Filing
- Jun 10, 2026VoteReported shareholder vote results. Filing
- Apr 10, 2026LeadershipFor the sole purpose of achieving an equal balance of membership among the three classes of the Board of Directors of Solid Biosciences Inc., effective at 4:00 p.m., Eastern Time, on April 10, 2026, Ilan Ganot, a member of the Board who was serving in Class III (which class will be up for election… Filing
- Mar 12, 2026AnnouncementThe Company announced positive new interim data from its Phase 1/2 INSPIRE DUCHENNE clinical trial, a Phase 1/2 first-in-human, open-label, single-dose, multicenter trial designed to evaluate the safety, tolerability and efficacy of SGT-003 in pediatric participants with Duchenne muscular dystrophy… Filing
- Mar 6, 2026AgreementSolid Biosciences Inc., a Delaware corporation, entered into a securities purchase agreement with certain institutional accredited investors, pursuant to which the Company agreed to issue and sell to the Investors in a private placement an aggregate of 14,973,257 shares of the Company’s common… Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Famous investors that hold SLDB
4 of the 50 well-known investors we track reported holding SLDB in their latest 13F filing. The largest position is Ken Griffin's, worth $15.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 2.10M | $15.2M | 0.0% | -26% |
| Israel Englander · Millennium Management | Q3 2026 | 237,633 | $1.7M | 0.0% | New |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 104,314 | $754K | 0.0% | +1% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 100,471 | $726K | 0.0% | -78% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named SLDB in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | RTW Investments, LP | 13G | 5.5% |
| Nov 16, 2026 | RTW Investments, LP | 13G | 5.5% |
| Nov 6, 2026 | RA Capital Management, L.P. | 13D/A | 10.8% |
| Nov 6, 2026 | RA Capital Management, L.P. | 13D/A | 10.8% |
Questions about Solid Biosciences Inc. (SLDB) stock
Who owns the most SLDB stock?
The largest reported owner of Solid Biosciences Inc. (SLDB) is Ra Capital Management, L.P., with 12.2% of the company. In total, 156 funds and institutions reported holding SLDB at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are SLDB insiders buying or selling?
In the last 12 months, SLDB insiders reported no open-market purchases and 27 sales worth $2.7M. The latest trade was on Oct 19, 2026. See every trade.
What is the short interest in SLDB?
As of Oct 30, 2026, 13.30M SLDB shares were sold short, 11.9% of the shares outstanding, up 8.2% from the report before. At the average daily volume of 1.24M shares, buying them all back would take about 10.7 trading days (days to cover). See the history.
Which famous investors hold SLDB?
4 of the 50 well-known investors we track reported SLDB in their latest 13F filing, including Ken Griffin, Israel Englander, Ken Fisher. The largest position is worth $15.2M. See all holders.
Executive pay
Solid Biosciences's chief executive was paid a total of $5.2M for the year ended Dec 31, 2025, up 7% from $4.9M the year before. In the last 12 months, Solid Biosciences's executives and directors bought no stock on the open market and sold $2.7M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.